Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 7/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11997788 | 0.83 | HIF1A (0.47) | HIF1AADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL3301771 | 0.69 | HIF1A (0.58) | HIF1AADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL259642 | 0.68 | LGALS3 (0.35) | SLC5A2LGALS3LGALS8OGAADORA2A | |
| SCHEMBL5046134 | 0.66 | SLC5A2 (0.50) | SLC5A2LGALS3LGALS8 | |
| SCHEMBL23547663 | 0.65 | LGALS3 (0.47) | SLC5A2LGALS3LGALS8 | |
| SCHEMBL23797741 | 0.65 | LGALS3 (0.47) | SLC5A2LGALS3LGALS8 | |
| SCHEMBL14949103 | 0.65 | SLC5A2 (0.52) | SLC5A2LGALS8 | |
| SCHEMBL19188686 | 0.65 | SLC5A2 (0.52) | SLC5A2LGALS8 | |
| SCHEMBL11199414 | 0.65 | HIF1A (0.40) | SLC5A2HIF1ASLC5A1 | |
| SCHEMBL11195779 | 0.64 | HIF1A (0.44) | SLC5A2HIF1ASLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | SLC5A2 1587/4885LGALS3 2773/4885LGALS8 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.